Updated:
Xencor
Xencor is a biotechnology firm based in Monrovia, California, founded in 1997. It develops monoclonal antibody therapeutics for autoimmune disorders, asthma,...
Xencor
Xencor is a biotechnology firm based in Monrovia, California, founded in 1997. It develops monoclonal antibody therapeutics for autoimmune disorders, asthma, allergic diseases, and cancer. The company has secured $94.9 million in total funding.
General information
Firm type
Asset Manager
Location
Region
North America
Country
United States
City
West Conshohocken
Corporate office
West Conshohocken, Menlo Park, Baltimore, Monrovia, San Francisco, Shanghai, Florida, New York, Waltham, Palo Alto, United States
Additional offices
Menlo Park · Baltimore · Monrovia · San Francisco · Shanghai · Florida · New York · Waltham · Palo Alto
Frequently asked questions
How does Xencor source proprietary deal flow?
Xencor does not source investments. It generates drug candidates through protein engineering and secures development partners who license its XmAb technology. These partnerships bring R&D funding, milestone payments, and royalties, replacing the VC-style portfolio construction found at family offices or venture firms.
Does Xencor participate in fund commitments or only direct deals?
Xencor makes no fund commitments. The company executes direct licensing deals and co-development agreements with pharmaceutical partners, earning milestones and royalties. It also invests directly in its own internal drug-development programs.
What investment stages does Xencor typically target?
Xencor is a therapeutics company, not an investor. It advances biologic drug candidates from discovery through clinical trials, with the most advanced in-house programs currently in Phase 2 for B-cell malignancies. Partnership deals occur across preclinical and clinical stages.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: